Evolving Epidemiology and Emerging Antifungal Resistance in Vulvovaginal Candidosis: Evidence from a Five-Year Survey
Pathogens · 16.05.2026 · 15 (5) · 538
DOI: 10.3390/pathogens15050538 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, online erschienen am 16.05.2026. Verfasst von Aristotelis Tsiakalos und 7 weiteren Autor:innen. Beteiligte Einrichtung: "Hygeia" General Hospital, 6 Erythrou Stavrou Street, 15123 Marousi, Greece. Hauptthemen laut MEDLINE: Candidiasis, Vulvovaginal, Antifungal Agents, Drug Resistance, Fungal, Candida. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eidikos Logariasmos Kondilion kai Ereunas, University of Patras, Special Account for Research Grants University of Athens.
Abstract (Originalsprache)
Candida species, particularly Candida albicans (C. albicans), are the leading cause of vulvovaginal candidosis (VVC) among women of reproductive age. In recent years, the epidemiology of VVC has shifted toward non-albicans Candida (NAC) species, accompanied by increasing antifungal resistance. This retrospective study evaluated the epidemiological profile of VVC and antifungal susceptibility patterns in Greece between 2020 and 2024 at a tertiary maternity and gynecological hospital. Species identification was performed using the VITEK® 2 system, and antifungal susceptibility followed EUCAST guidelines. A total of 526 vaginal swab samples were analyzed, comprising C. albicans (57.9%) and NAC species (42.1%). The median age was 36.3 years (range: 18–92). Among NAC isolates, Nakaseomyces glabratus (26.4%) predominated, followed by Pichia kudriavzevii (7.6%), Candida parapsilosis (5.1%), and Candida tropicalis (3.0%). Resistance rates among C. albicans isolates increased from 9.3% in 2020 to 22.3% (fluconazole) and 20.9% (itraconazole) in 2024. Voriconazole resistance was not detected until 2023 and 2024, when rates rose to 3.2% and 15.2%. Fluconazole resistance was observed in C. parapsilosis (3.5%) and C. tropicalis (12.5%). Echinocandin resistance remained low overall, except for N. glabratus, which demonstrated a 13.8% resistance rate to caspofungin. These findings highlight the need for surveillance, improved diagnostics and antifungal stewardship.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- "Hygeia" General Hospital, 6 Erythrou Stavrou Street, 15123 Marousi, Greece.
- Department of Internal Medicine, University General Hospital of Patras, 26504 Rio, Greece.
- Department of Medicine, University of Patras, 26504 Rio, Greece.
- Department of Microbiology, Medical School of Athens, National and Kapodistrian University of Athens, 75 Mikras Asias Str., 11527 Athens, Greece.
- "Leto" General, Maternity & Gynecology Clinic, Mouson 7-13 Street, 11524 Athens, Greece.
- Department of Medicine, Brown University, Providence, RI 02912, USA.
ORCID-Profile: Vassiliki C Pitiriga, Karolina Akinosoglou
Förderung
- Eidikos Logariasmos Kondilion kai Ereunas, University of Patras
- Special Account for Research Grants University of Athens
Zitieren
APA
Tsiakalos, A., Papageorgiou, D., Pitiriga, V. C., Vogiatzi, C., Ziakas, P. D., Routsias, I., Dimitroulia, E., & Akinosoglou, K. (2026). Evolving Epidemiology and Emerging Antifungal Resistance in Vulvovaginal Candidosis: Evidence from a Five-Year Survey. Pathogens, 15(5), 538. https://doi.org/10.3390/pathogens15050538
Vancouver
Tsiakalos A, Papageorgiou D, Pitiriga VC, Vogiatzi C, Ziakas PD, Routsias I, et al. Evolving Epidemiology and Emerging Antifungal Resistance in Vulvovaginal Candidosis: Evidence from a Five-Year Survey. Pathogens. 2026;15(5):538. doi:10.3390/pathogens15050538
BibTeX
@article{Tsiakalos2026,
author = {Tsiakalos, Aristotelis and Papageorgiou, Despoina and Pitiriga, Vassiliki C and Vogiatzi, Christina and Ziakas, Panayotis D and Routsias, Ioannis and Dimitroulia, Evangelia and Akinosoglou, Karolina},
title = {Evolving Epidemiology and Emerging Antifungal Resistance in Vulvovaginal Candidosis: Evidence from a Five-Year Survey},
journal = {Pathogens},
year = {2026},
volume = {15},
number = {5},
pages = {538},
doi = {10.3390/pathogens15050538}
}
EUVIMED